We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serum Vimentin Predicts Mortality in Pediatric Severe Sepsis

By LabMedica International staff writers
Posted on 14 Jun 2022
Print article
Image: The Human P-Selectin ELISA Kit – serum vimentin levels were positively correlated with P-selectin in pediatric severe sepsis (Photo courtesy of MULTI SCIENCES(LIANKE) BIOTECH, CO.,LTD).
Image: The Human P-Selectin ELISA Kit – serum vimentin levels were positively correlated with P-selectin in pediatric severe sepsis (Photo courtesy of MULTI SCIENCES(LIANKE) BIOTECH, CO.,LTD).

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. It is a leading cause of death worldwide in the pediatric population. Vascular hyperpermeability by loss of endothelial barrier integrity is a hallmark of sepsis.

Inflammatory response during sepsis triggers endothelial barrier dysfunction, consequently resulting in not just vascular leak and edema, but even shock and organ failure. The cytoskeletal filament vimentin is inherent to the endothelial phenotype and is critical for the proper function of endothelial cells. The association between serum vimentin and the prognosis of sepsis in children remains indeterminate.

Critical Care doctors at the Shanghai Children's Hospital (Shanghai, China) conducted a prospective study of pediatric severe sepsis (PSS) cases who were admitted to the pediatric intensive care unit (PICU) from January 2018 to December 2020. A total of 108 patients with PSS with a median age of 19.5 month were enrolled.

The laboratory indexes included routine blood indexes (white blood cell, platelet, C-reactive protein, lactate dehydrogenase, lactic acid [Lac]), cytokines (interleukin [IL]-6, IL-10, tumor necrosis factor-α), immune indexes (NK%, CD4+ CD8+, CD19), biomarkers of endothelial cell injury (serum intercellular adhesion molecule, serum vascular cell adhesion molecule, P-selectin).

For the serum vimentin assay, serum was collected within six hours of PICU admission and stored at –80 °C. Serum vimentin levels were determined using enzyme-linked immunosorbent assays: Human Vimentin ELISA Kit (MultiScience, LIANKE Biotech, CO., LTD, Hangzhou, China) with the range of 0.2–60 ng/mL. ELISA was performed in duplicate, and other assays were performed in strict accordance with the manufacturers’ instructions.

The scientists reported that the hospital mortality rate was 19.44% (21/108). Comparing with healthy controls, serum vimentin levels on PICU admission were significantly higher in patients with PSS. The area under the ROC curve for vimentin to predict the hospital mortality was 0.712 (95% CI: 0.578–846) with a sensitivity of 71.4% and a specificity of 70.1%. Moreover, hospital mortality was significantly higher in patients with vimentin level over the cutoff value of 24.53 ng/mL than in patients with vimentin level below 24.53 ng/L.

Serum levels of sICAM-1, sVCAM-1 and P-selectin displayed an increased tendency in non-survivors compared with survivors. NK (%) was significantly lower in non-survivors than in survivors (2.94 versus 4.34), whereas serum Lac levels at PICU admission displayed higher tendency in non-survivors (2.6 mmol/L versus 2.1 mmol/L). According to the results of correlation analysis, serum vimentin levels were positively correlated with P-selectin and NK (%).

The authors concluded that serum vimentin level as an indicator of endothelial injury is associated with the prognosis of PSS, and serum vimentin level ≥24.53 ng/mL on PICU admission predicts high risk for hospital mortality in PSS. The study was published in the August 1 2022 issue of the International Journal of Infectious Diseases.

Related Links:
Shanghai Children's Hospital 
LIANKE Biotech 

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
New
Electrophoresis Automated System
Auto Scanion

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.